clinical trial · NCT07069556
ColoSense Post-Approval Study
Geneoscopy, Inc.·—·recruiting·n = 12,500
Colorectal Cancer (Diagnosis)ColoSense
brief summary
The post-approval study (PAS) described here will supplement existing data generated in the CRC-PREVENT clinical trial. The primary outcomes of this supplemental study will include: clinical sensitivity, clinical specificity, positive predictive value (PPV), and negative predictive value (NPV) of ColoSense.
started
Sep 5, 2025
primary completion
Sep 1, 2028
completion
Sep 1, 2030
last updated
Nov 21, 2025
official title
ColoSense Post Approval Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol